Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06880562 · ClinicalTrials.gov registry record · NA
The RESPLASH Study
A NA study, sponsored by Tulane University.
- Not yet
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT06880562 is a NA study that has not yet begun recruiting, run by Tulane University. The registered enrollment target is 20 participants.
The verdict
NCT06880562, a NA study, has not yet begun recruiting, sponsored by Tulane University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
To assess the safety and effectiveness of renal artery denervation with subsequent splanchnic nerves denervation via catheter-based radiofrequency ablation in improving blood pressure and glycemic control in patients with resistant hypertension and type 2 diabetes.
Interventions
- DEVICE Splanchnic Nerve Denervation
- DEVICE Renal Denervation Only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06880562
The ClinicalTrials.gov registry entry for NCT06880562 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Splanchnic Nerve Denervation is the first listed.
NCT06880562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06880562 about?
NCT06880562 is a clinical study titled "The RESPLASH Study". To assess the safety and effectiveness of renal artery denervation with subsequent splanchnic nerves denervation via catheter-based radiofrequency ablation in improving blood pressure and glycemic control in patients with resistant hypertension and type 2 diabetes.
What is the current status of trial NCT06880562?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-06. Estimated completion is 2027-06.
What interventions are being tested in trial NCT06880562?
The interventions under investigation include: Splanchnic Nerve Denervation (DEVICE), Renal Denervation Only (DEVICE).
Who is sponsoring clinical trial NCT06880562?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.